

Amendments to the Claims

Please cancel Claims 1, 5 and 11-13.

Please amend Claims 3, 4, 7 and 8.

Please add New Claims 14-19.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Canceled)
2. (Canceled)
3. (Currently Amended) A method of treating TNF α -mediated psoriasis in a human comprising administering to the human an effective tumor necrosis factor alpha ~~(TNF)-inhibiting~~ (TNF α)-inhibiting amount of chimeric ~~anti-TNF~~ anti-TNF α monoclonal antibody cA2.
4. (Currently Amended) A method of treating TNF α -mediated psoriasis in a human comprising administering to the human at least one chimeric anti-TNF α monoclonal antibody cA2, or a tumor necrosis factor binding fragment thereof.
5. (Canceled)
6. (Canceled)
7. (Currently Amended) A method of treating TNF α -mediated psoriasis in a human comprising administering to the human an effective tumor necrosis factor alpha ~~(TNF)-inhibiting~~ (TNF α)-inhibiting amount of an ~~anti-TNF~~ anti-TNF α chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF α chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.

8. (Currently Amended) A method of treating TNF α -mediated psoriasis in a human comprising administering to the human an effective tumor necrosis factor alpha (~~TNF~~)-~~inhibiting~~ (TNF α)-~~inhibiting~~ amount of an ~~anti-TNF~~ anti-TNF α chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF α chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5 and an IgG1 human constant region.
9. (Original) The method of claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. (Original) The method of claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.

Claims 11.-13. (Canceled)

14. (New) The method of Claim 3 wherein the chimeric anti-TNF α monoclonal antibody cA2 is administered to the human by means of parenteral administration.
15. (New) The method of Claim 3 wherein the chimeric anti-TNF α monoclonal antibody cA2 is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.
16. (New) The method of Claim 3 wherein the chimeric anti-TNF α monoclonal antibody cA2 is administered to the human orally.
17. (New) The method of Claim 3 wherein said TNF α -inhibiting amount of said chimeric anti-TNF α monoclonal antibody cA2 comprises a single or divided dose of about 0.1 - 50 mg/kg.
18. (New) The method of Claim 17 wherein the single or divided dose is selected from the

group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.

19. (New) The method of Claim 3 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: radiotherapeutics, cytotoxic drugs, monoclonal antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.